Akyürek, S.Yavaş, G.2020-03-262020-03-2620131812-9269https://hdl.handle.net/20.500.12395/30191Neoadjuvant chemotherapy for primary breast cancer is the gold standard in the treatment of locally advanced, inoperable breast cancer, and also based on a large body of evidence has become a standard treatment option for patients with operable disease, who are clear candidates for adjuvant chemotherapy. There are several advantages of administering neoadjuvant chemotherapy: tumor downstaging, improving the chance of breast conserving surgery, in vivo assessment of tumor sensitivity to the chosen therapeutic regimen, and early control of micro-metastatic disease. However there are substantially less data to aid in determining which patients treated with neo-adjuvant chemotherapy warrant postmastectomy radiotherapy. According to the recent literature, patients who require mastectomy after systemic therapy should receive postmastectomy radiotherapy. Copyright © Experimental Oncology, 2013.eninfo:eu-repo/semantics/closedAccessBreast cancerLocally advancedNeoadjuvant chemotherapyRadiotherapyReview35426727124382436Q4